SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 open-label extension data for deramiocel, presented at the World Muscle Society meeting, is driving attention; traders point to delayed-start results suggesting slower upper-limb decline as support for the Duchenne muscular dystrophy drugs pending FDA review. The reaction is largely optimistic, but some question whether the open-label evidence and disputed statistical analysis plan will satisfy regulators.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming fiscal fourth-quarter report is the dominant focus, with traders expecting strong results and guidance amid tight DRAM and NAND supply, resilient pricing, and AI-related memory demand. Bullish expectations are countered by concerns that good news is already priced in, the stock could sell off after results, and the memory upcycle may not last; a new Netlist patent action is a secondary concern.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A judges pause in the federal cannabis Schedule III rescheduling process while the DEA responds to a GAO report on procedural gaps has raised concerns about further delays. Traders disagree on the implications: some view it as a limited procedural step and buying opportunity, while others worry it could push rescheduling further out and weigh on cannabis stocks.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving the sharp rally. Traders are broadly celebrating the commercial momentum and speculating about short covering, while others warn the move may be overextended and raise dilution concerns; upcoming cancer-trial updates are also part of the bullish discussion.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO is under pressure after the FHFA opened Fannie Mae and Freddie Mac mortgage pricing to VantageScore alongside FICO, with Rocket Mortgage also signaling a preference for the competing model on eligible loans. Traders fear this could weaken FICOs mortgage-scoring moat and pricing power, while others argue the selloff overstates the threat because FICO remains entrenched and its broader business is still growing.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Positive Phase 3 results for Vandas HETLIOZ in delayed sleep-wake phase disorder are driving attention, with traders highlighting that the study met its primary endpoint. The reaction is broadly optimistic about the pipeline and potential regulatory progress, though some question whether the share-price move will hold.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods app and platform outage is drawing attention, with users reporting frozen access and trading problems and expressing frustration over potential losses; some speculate about a hack, while others attribute the disruption to a technical or AWS issue and say service has recovered.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is drawing attention amid a prolonged selloff and fresh multi-year lows, as traders focus on slowing ad growth, weak guidance, and competition from Amazon and other platforms. Bears see more downside and criticize management, while bulls argue the cash-generative business is oversold and could recover if growth improves.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires selection for the Space Forces NITE-STAR contract vehicle, which has a shared ceiling of about $980 million, is drawing attention as a defense-space opportunity, though it guarantees no revenue for the company. Traders see the award as validation of Redwires pipeline, while skeptics call it a limited catalyst and point to volatile trading and broader market pressure.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeings 737 MAX software glitch and the FAAs review, which could delay MAX 10 certification, are driving concern about regulatory scrutiny and future deliveries. Bears see another setback for the recovery, while bulls argue the issue is manageable and the selloff is overdone.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.read more...

MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching

Equity

MannKind and Rose Pharma are partnering to develop an inhaled weight-loss treatment using the Technosphere dry-powder inhalation technology.

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.read more...

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost  

FDA approved MannKind’s Furoscix ReadyFlow on Friday.

MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds 

The FDA is expected to announce its decision on MannKind’s sNDA on July 26, 2026.


What This MannKind Filing Reveals About Three Years of Underperformance

Key PointsThis MannKind insider filing details the disposition of 46,795 shares...

MannKind Corporation (Nasdaq: MNKD) is a commercial-stage biopharmaceutical company with a diversified business spanning marketed products, strategic collaborations and a proprietary development pipeline. Focused on cardiometabolic and orphan lung diseases, MannKind’s portfolio includes Afrezza® (inhaled mealtime insulin), FUROSCIX® (furosemide injection for fluid overload) and V-Go® (all-in-one insulin delivery patch). Its proprietary Technosphere® technology is also utilized in Tyvaso DPI® (an inhaled treatment for pulmonary hypertension), marketed by United Therapeutics. The company is advancing additional inhaled therapies and drug-device combination products designed to address serious unmet medical needs. Founded by Alfred E. Mann in 1991, MannKind is headquartered in Danbury, Connecticut.

Mannkind Corp

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Feed

News

Sentiment

Earnings

Fundamentals

Info

MNKD News